Primordial Genetics today announced the first closing of its Series A-2 financing round, including a group of 5 private investors.
The company will use the capital it has raised to support additional R&D activities to develop superior microbial strains for production of high-value proteins including human therapeutic proteins and industrial enzymes.
Related Articles
-
Richard Schneeberger PhD, MBA joins Primordial Genetics as business consultant
Richard Schneeberger, PhD, MBA has joined Primordial Genetics Inc as acting Director of Business Development. Richard Schneeberger, PhD, MBA...
-
-
Primordial Genetics goes live on Fundable
Primordial Genetics joins Fundable, a crowd-sourcing platform and investment community that features small companies and allows them to connect...
-
-
Primordial Genetics and Denovium Collaborate to Impact the Diagnosis, Prevention & Treatment of Human Diseases
The Research is Supported by the National Human Genome Research Institute of the National Institutes of Health Primordial Genetics,...
-
The Science ‘Rebel’ Who’s Teaching Microbes to be More Productive
On this episode of the J&J Innovation Podcast, we sit down with Helge Zieler, founder and President of Primordial Genetics, about...
-
-
Go Beyond Investing conducts due diligence on Primordial Genetics
Go Beyond Investing (https://go-beyond.biz/) is a FinTech company transforming angel investing into a new scalable asset class for small...
0 Comments